🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Sreepriya Prasannan

Sreepriya Prasannan

Life Science Journalist & Editor

Sreepriya Prasannan is the Founder and Lead Editor of Priya Life Science. With a deep passion for the Irish pharmaceutical and MedTech sectors, she specializes in sharing actionable career insights, digital regulatory trends, and GMP compliance strategies.

42
Articles
7
Topics
1219
Min Published
LinkedIn
Filter: All 42 Industry 75 Regulatory Affairs 42 Pharmaceutical 25 Biotechnology 16 MedTech 16 LinkedIn 12 Clinical Trials 5

Articles in Regulatory Affairs

Page 3 of 4 — 42 articles
Eli Lilly Adapts Direct-to-Patient Model for UK Market with LillyDirect Launch
Regulatory Affairs
Eli Lilly Adapts Direct-to-Patient Model for UK Market with LillyDirect Launch
Eli Lilly has successfully brought its LillyDirect service to the UK. Adapted to comply with strict local regulations, the service partners with regulated healthcare organizations to offer secure, anti-counterfeit delivery of high-demand therapies like Mounjaro directly to patients' doors.
25 Jun 2026 4 min
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Regulatory Affairs
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.
25 Jun 2026 4 min
How to Build a Powerful Personal Brand in Pharma
Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma
Building a personal brand in the pharmaceutical industry requires balancing thought leadership with strict confidentiality and professionalism.
23 Jun 2026 4 min
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.
22 Jun 2026 14 min
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
21 Jun 2026 5 min
Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules
Regulatory Affairs
Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules
Breckenridge Pharmaceutical has initiated a voluntary recall of hundreds of thousands of bottles of Duloxetine Delayed-Release Capsules due to the presence of nitrosamine impurities exceeding FDA limits.
16 Jun 2026 4 min
Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing
Regulatory Affairs
Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing
The Competition and Consumer Protection Commission (CCPC) has launched a comprehensive market study into Ireland's retail pharmacy sector, targeting opaque pricing practices and a lack of competition.
16 Jun 2026 5 min
Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029
Regulatory Affairs
Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029
The Irish government signs major new Framework Agreements with MFI and IPHA, aiming to reduce patient wait times for innovative treatments to 180 days by 2029.
15 Jun 2026 5 min
The GLP-1 Dilemma: Ireland’s Battle Over Blockbuster Weight-Loss Drugs
Regulatory Affairs
The GLP-1 Dilemma: Ireland’s Battle Over Blockbuster Weight-Loss Drugs
The Health Service Executive (HSE) is facing intense budgetary pressure as clinical demand for GLP-1 obesity medications skyrockets. We break down the restrictive funding, the "dreadful dichotomy" of access, and the surge in illegal online sales.
12 Jun 2026 4 min
FDA 21 CFR Part 211 vs. EU GMP Annex 1: Key Differences
Regulatory Affairs
FDA 21 CFR Part 211 vs. EU GMP Annex 1: Key Differences
A comprehensive breakdown of the core differences between US FDA 21 CFR Part 211 and EU GMP Annex 1 for sterile and non-sterile pharmaceutical manufacturing.
11 Jun 2026 4 min
CAPA vs. Root Cause Analysis (RCA) in Pharma
Regulatory Affairs
CAPA vs. Root Cause Analysis (RCA) in Pharma
Understanding the critical distinction between Root Cause Analysis (RCA) and Corrective and Preventive Actions (CAPA) in pharmaceutical quality management systems.
11 Jun 2026 5 min
AQL vs. RQL: Choosing the Right Sampling Plan
Regulatory Affairs
AQL vs. RQL: Choosing the Right Sampling Plan
A technical guide to understanding Acceptable Quality Limit (AQL) versus Rejectable Quality Limit (RQL) in pharmaceutical statistical sampling and batch release.
11 Jun 2026 5 min